Cargando…

Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials

INTRODUCTION: Despite the challenge of a global pandemic, 2020 has been an invaluable year in cardiology research with numerous important clinical trials published or presented virtually at major international meetings. This article aims to summarise these trials and place them in clinical context....

Descripción completa

Detalles Bibliográficos
Autores principales: Kearney, Aileen, Linden, Katie, Savage, Patrick, Menown, Ian B. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040014/
https://www.ncbi.nlm.nih.gov/pubmed/33844133
http://dx.doi.org/10.1007/s12325-021-01711-z
_version_ 1783677708251693056
author Kearney, Aileen
Linden, Katie
Savage, Patrick
Menown, Ian B. A.
author_facet Kearney, Aileen
Linden, Katie
Savage, Patrick
Menown, Ian B. A.
author_sort Kearney, Aileen
collection PubMed
description INTRODUCTION: Despite the challenge of a global pandemic, 2020 has been an invaluable year in cardiology research with numerous important clinical trials published or presented virtually at major international meetings. This article aims to summarise these trials and place them in clinical context. METHODS: The authors reviewed clinical trials presented at major cardiology conferences during 2020 including the American College of Cardiology, European Association for Percutaneous Cardiovascular Interventions, European Society of Cardiology, Transcatheter Cardiovascular Therapeutics and the American Heart Association. Trials with a broad relevance to the cardiology community and those with potential to change current practice were included. RESULTS: A total of 87 key cardiology clinical trials were identified for inclusion. New interventional and structural cardiology data included trials evaluating bifurcation percutaneous coronary intervention (PCI) techniques, intravascular ultrasound (IVUS)-guided PCI, instantaneous wave-free (iFR) physiological assessment, new generation stents (DynamX bioadaptor), transcatheter aortic valve implantation (TAVI) in low-risk patients, and percutaneous mitral or tricuspid valve interventions. Preventative cardiology data included new data with proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab), omega-3 supplements, evinacumab and colchicine in the setting of chronic coronary artery disease. Antiplatelet data included trials evaluating both the optimal length of course following PCI and combination of antiplatelet agents and regimes including combination antithrombotic therapies for patients with atrial fibrillation (AF). Heart failure data included the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors (sotagliflozin, empagliflozin and dapagliflozin) and mavacamten in hypertrophic cardiomyopathy. Electrophysiology trials included early rhythm control in AF and screening for AF. CONCLUSION: This article presents a summary of key clinical cardiology trials during the past year and should be of relevance to both clinicians and cardiology researchers.
format Online
Article
Text
id pubmed-8040014
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-80400142021-04-12 Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials Kearney, Aileen Linden, Katie Savage, Patrick Menown, Ian B. A. Adv Ther Review INTRODUCTION: Despite the challenge of a global pandemic, 2020 has been an invaluable year in cardiology research with numerous important clinical trials published or presented virtually at major international meetings. This article aims to summarise these trials and place them in clinical context. METHODS: The authors reviewed clinical trials presented at major cardiology conferences during 2020 including the American College of Cardiology, European Association for Percutaneous Cardiovascular Interventions, European Society of Cardiology, Transcatheter Cardiovascular Therapeutics and the American Heart Association. Trials with a broad relevance to the cardiology community and those with potential to change current practice were included. RESULTS: A total of 87 key cardiology clinical trials were identified for inclusion. New interventional and structural cardiology data included trials evaluating bifurcation percutaneous coronary intervention (PCI) techniques, intravascular ultrasound (IVUS)-guided PCI, instantaneous wave-free (iFR) physiological assessment, new generation stents (DynamX bioadaptor), transcatheter aortic valve implantation (TAVI) in low-risk patients, and percutaneous mitral or tricuspid valve interventions. Preventative cardiology data included new data with proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab), omega-3 supplements, evinacumab and colchicine in the setting of chronic coronary artery disease. Antiplatelet data included trials evaluating both the optimal length of course following PCI and combination of antiplatelet agents and regimes including combination antithrombotic therapies for patients with atrial fibrillation (AF). Heart failure data included the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors (sotagliflozin, empagliflozin and dapagliflozin) and mavacamten in hypertrophic cardiomyopathy. Electrophysiology trials included early rhythm control in AF and screening for AF. CONCLUSION: This article presents a summary of key clinical cardiology trials during the past year and should be of relevance to both clinicians and cardiology researchers. Springer Healthcare 2021-04-12 2021 /pmc/articles/PMC8040014/ /pubmed/33844133 http://dx.doi.org/10.1007/s12325-021-01711-z Text en © Crown 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Kearney, Aileen
Linden, Katie
Savage, Patrick
Menown, Ian B. A.
Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
title Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
title_full Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
title_fullStr Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
title_full_unstemmed Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
title_short Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
title_sort advances in clinical cardiology 2020: a summary of key clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040014/
https://www.ncbi.nlm.nih.gov/pubmed/33844133
http://dx.doi.org/10.1007/s12325-021-01711-z
work_keys_str_mv AT kearneyaileen advancesinclinicalcardiology2020asummaryofkeyclinicaltrials
AT lindenkatie advancesinclinicalcardiology2020asummaryofkeyclinicaltrials
AT savagepatrick advancesinclinicalcardiology2020asummaryofkeyclinicaltrials
AT menownianba advancesinclinicalcardiology2020asummaryofkeyclinicaltrials